Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Chief Financial Officer Transition On March 11, 2024, Turning Point Brands, Inc. (the “Company”) announced that Louie Reformina, Senior Vice President and Chief Financial Officer of the Company, would be stepping down from his position in order to pursue other opportunities, effective as of March 8, 2024. Mr. Reformina’s decision to pursue other opportunities was not the result of any dispute or disagreement regarding any matter relating to the Company’s operations, policies or practices. The Board of Directors of the Company (the “Board”) has appointed Andrew Flynn to serve as Senior Vice President and Chief Financial Officer of the Company, with an anticipated start date of April 1, 2024, to take Mr. Reformina’s position. Andrew Flynn, age 48, previously served as the CFO of Connected Cannabis Co. (“Connected”) from September 2021 until March 2024, where he was responsible for bringing sustained profitable growth, expanding geographically and recapitalizing the company. Prior to joining Connected, from June 2019 until September 2021, Mr. Flynn served in various positions at Juul Labs, including as Sr. Vice President. Earlier in his career, Mr. Flynn served as Vice President of Finance at James Hardie Building Products, and Vice President of Finance at Arrow Electronics. Mr. Flynn holds a BS from Indiana University and an MBA from the University of Colorado, Denver. There are no family relationships between Mr. Flynn and any director or other executive officer of the Company, nor are there any transactions to which the Company was or is a participant and in which Mr. Flynn has a material interest subject to disclosure under Item 404(a) of Regulation S-K. There are no arrangements or understandings between Mr. Flynn and any other person pursuant to which he was selected as an officer of the Company. Flynn Employment Agreement In connection with Mr. Flynn’s appointment, the Company entered into an employment agreement with Mr. Flynn (the “Employment Agreement”), to become effective as of the date on which he commences employment with the Company, which is expected to occur no later than April 1, 2024 (such date, the “Effective Date”). The Employment Agreement provides for an initial term of one year commencing on the Effective Date, subject to automatic extensions for successive one-year terms unless earlier terminated, or unless either party provides notice of non-renewal at least 60 days prior to the end of the applicable term. The Employment Agreement provides for an annual base salary of $400,000, subject to adjustment by the Board, and a target annual bonus equal to 50% of annual base salary, subject to the terms and conditions of the Company’s annual bonus program in effect from time to time. Mr. Flynn will also be eligible to participate in the medical, dental and 401(k) savings benefit plans offered to the Company’s similarly situated employees. Mr. Flynn will also be eligible to participate in the Company's long-term equity incentive program on terms consistent with other senior executives of the Company, as determined by the Board. In the event that Mr. Flynn’s employment is terminated by the Company without “cause” or Mr. Flynn resigns for “good reason” (each as defined in the Employment Agreement), other than during the one-year period immediately following a “change of control” (as defined in the Employment Agreement), Mr. Flynn would be entitled to severance payments comprised of the following: (1) accrued compensation and benefits; (2) continuation of his then-current base salary for 12 months, to be paid in accordance with the Company’s normal payroll practices; (3) a cash severance bonus equal to the average annual cash bonus received by Mr. Flynn for the 24-month period prior to the termination date; and (4) a lump sum payment equal to the cost of COBRA continuation coverage for Mr. Flynn and his eligible dependents for 12 months. In the event that Mr. Flynn’s employment is terminated by the Company without “cause” or Mr. Flynn resigns for “good reason” during the one-year period immediately following a “change of control”, Mr. Flynn would be entitled to severance payments comprised of the following (in lieu of any other severance payments under the Employment Agreement): (1) the accrued compensation and benefits; (2) continuation of his then-current base salary for 24 months, to be paid in accordance with the Company’s normal payroll practices; (3) a cash severance bonus equal to two-times the average annual cash bonus received by Mr. Flynn for the 24-month period prior to the termination date; and (4) a lump sum payment equal to the cost of COBRA continuation coverage for Mr. Flynn and his eligible dependents for 12 months. The foregoing severance payments and other benefits are subject to Mr. Flynn executing and delivering an effective release of claims to the Company. In the event of Mr. Flynn’s death or disability, he would be entitled to receive a lump sum payment equal to the cost of COBRA continuation coverage for Mr. Flynn (except in the event of his death) and his eligible dependents for six months. Pursuant to the Employment Agreement, Mr. Flynn will be subject to certain restrictive covenants, including non-competition and non-solicitation restrictions during the employment term, and for a post-termination period equal to the number of months he is entitled to receive salary continuation pursuant to the severance provisions described above. The foregoing description is qualified by reference to the full text of the Employment Agreement. A copy of the Employment Agreement is filed as